Abstract
The introduction of the ocular hypotensive medication bimatoprost in 2001 has widened the spectrum of options available for intraocular pressure (IOP) lowering in glaucoma. The purpose of this supplement is to provide an update on bimatoprost (Lumigan, Allergan) from a pharmacological, clinical, and pharmacoeconomic perspective, in order to gain a better appreciation of its role in glaucoma management.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call